UbiDX
Kate Sharadin is an accomplished entrepreneur and executive with extensive experience in the healthcare and life sciences sectors. As the Chief Executive Officer and Founder of UbiDX since May 2021, Kate leads the development of a platform focused on precision prevention and disease management through real-time biochemical monitoring and AI-driven insights. Prior to UbiDX, Kate founded eQuility.net, assembling a diverse team to innovate non-drug technologies for neural modulation. Kate also co-founded MEDX Xelerator, a medical device and digital health incubator, and held senior roles at Intellectual Ventures, The Sharadin Group, Pacific Growth Equities, GKM, Preferred Capital Markets, and Roth Capital, where expertise in strategic advisory, business development, and investment in medical technologies and healthcare informatics was honed.
This person is not in any teams
UbiDX
1 followers
UbiDX is developing a novel, digital, patient-centric diagnostics and testing platform that will be as sensitive as laboratory tests but for use in the home. Our platform will provide users, along with their caregivers, a simple, easy-to-use system to rapidly diagnose, measure and monitor diseases. This will be accomplished through the UbiDX architecture that integrates key UbiDX-generated biochemical data with physiological and digital data while drawing on artificial intelligence to be evidence-based, personalized and more cost effective. The UbiDX platform will be key to the shift from unplanned emergencies to planned interventions providing a new way to combat diseases.